选择性RET抑制剂在晚期遗传性甲状腺髓样癌患者中的疗效与安全性
单中心回顾性队列纳入23例晚期遗传性甲状腺髓样癌患者,接受选择性RET抑制剂(selpercatinib 13例或pralsetinib 10例)治疗,最佳影像学缓解为部分缓解18例(78%)、疾病稳定5例(22%),中位总生存期51个月(CI 40.5–61.3),中位无进展生存期未达到,常见不良事件为ALT升高(48%)等,未发生5级治疗相关不良事件。
要点
- 晚期遗传性甲状腺髓样癌接受选择性RET抑制剂,部分缓解率78%(18/23)。
- 中位总生存期51个月(CI 40.5–61.3),中位无进展生存期未达到。
- 常见不良事件为ALT升高(48%)和QT间期延长(39%),8例(35%)因不良事件减量。
核心结论
- 在晚期遗传性甲状腺髓样癌患者中,选择性RET抑制剂似乎安全有效,结局与以散发性甲状腺髓样癌为主的临床试验队列相似。
- 缓解持续时间和不良事件特征与散发性甲状腺髓样癌相似,但需更长随访和更大样本量确认。
研究设计与样本
- 单中心回顾性队列研究,纳入三级癌症中心接受选择性RET抑制剂治疗的遗传性甲状腺髓样癌患者。
- 共23例可评估患者:MEN2A 15例(65%),MEN2B 8例(35%)。
- RET抑制剂起始中位年龄51岁(范围15–79),所有患者均有远处转移,52%(12/23)既往接受过系统治疗(中位数1,范围0–3)。
- 治疗药物为selpercatinib(n=13)或pralsetinib(n=10),57%(13/23)在临床试验内接受治疗。
- RET抑制剂中位治疗时长25个月(范围3–72),中位随访时长49个月(范围9–72)。
主要发现
- 最佳影像学缓解为部分缓解18例(78%)、疾病稳定5例(22%)。
- 中位总生存期51个月(置信区间40.5–61.3),中位无进展生存期未达到。
- 数据截止时11/23(48%)患者因持续缓解仍在用药。
- 最常见不良事件为丙氨酸氨基转移酶升高(48%)和天冬氨酸氨基转移酶升高(26%)、口干(39%)、QT间期延长(39%)、乏力(35%)、高血压(26%)。
- 8例(35%)患者因不良事件减量,未发生5级治疗相关不良事件。
关键数值与推荐
- 主要终点为采用RECIST v1.1评估的总体缓解率。
- 次要终点包括总生存期、无进展生存期、生化缓解率和安全性。
- 除1–2级ALT升高和QT间期延长外,大多数不良事件发生率与已发表临床试验相当。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需更长随访和更大样本量以确认缓解持续时间和不良事件特征与散发性甲状腺髓样癌相似。
- 原文为单中心回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Two selective RET inhibitors (RETis) are effective in treating REarranged during Transfection (RET)-altered medullary thyroid carcinoma (MTC), but clinical trials did not distinguish responses between hereditary MTC (hMTC) and sporadic MTC (sMTC) cases. We reviewed our single-center experience using a RETi to treat advanced hMTC. Methods: We conducted a retrospective cohort study of patients with hMTC treated with a selective RETi at a tertiary cancer center. The primary outcome was overall response rate using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Secondary end points included overall survival (OS), progression-free survival (PFS), biochemical response rate, and safety. Results: We identified 23 evaluable patients as follows: 15 (65%) multiple endocrine neoplasia (MEN)2A and 8 (35%) MEN2B. Median age at start of RETi was 51 years (range, 15-79). All patients had distant metastases, and 52% (12/23) had received prior systemic therapy (median = 1, range, 0-3). Patients were treated with selpercatinib (n = 13) or pralsetinib (n = 10), 57% (13/23) within a clinical trial. Median duration of RETi was 25 months (range, 3-72) with 11/23 (48%) patients remaining on drug at data cutoff due to an ongoing response. Median duration of follow-up was 49 months (range, 9-72). Best radiographical response was partial response in 18 (78%) and stable disease in 5 (22%) patients. Median OS was 51 months (confidence interval, 40.5-61.3); median PFS was not reached. Most common adverse events (AEs) were increased alanine aminotransferase (ALT) (48%) and aspartate aminotransferase (26%), dry mouth (39%), QT interval prolongation (39%), fatigue (35%), and hypertension (26%). AEs led to dose reductions in eight (35%) patients. No grade 5 treatment-related AEs occurred. While the germline nature of the RET pathogenic variant in hMTC could hypothetically result in increased drug-related toxicity, the incidence of most AEs, other than grade 1-2 ALT elevation and QT interval prolongation, was comparable to published clinical trials. Conclusions: In patients with advanced hMTC, selective RETis appear safe and effective with outcomes similar to clinical trial cohorts, which mostly comprised patients with sMTC. Duration of response and AE profile was similar to sMTC, although longer follow-up and larger patient numbers are needed to confirm this.
引用
- Hamidi S, Yedururi S, Hu MI, et al. Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma. Thyroid. 2024. PMID: 39630530. doi:10.1089/thy.2024.0495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。